Evidence map›Paper›PMID 42398036›Full record

ArticleJMIR research protocols2026

Identification of Potentially Inappropriate Medications for Adults Below 65 Years: Protocol for a Modified Delphi Study.

Eva Filosa, Nicole Schönenberger, Utibe R Essien, Camille Gagnon, Danijela Gnjidic, Lisa Kouladjian O'Donnell, Elizabeth Manias, Lisa M McCarthy, Frank Moriarty, Jérôme Nguyen-Soenen and 9 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eva FilosaDivision of Clinical and Translational Research, Faculty of Medicine and Health Sciences, McGill University, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada, 1 (514) 934-1934 ext 36134.ORCID 0009-0005-9542-0685
Nicole SchönenbergerClinical Pharmacology and Toxicology, Department of General Internal Medicine, University Hospital of Bern, Bern, Switzerland.ORCID 0000-0001-5530-8502
Utibe R EssienDivision of General Internal Medicine & Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.ORCID 0000-0002-4494-5028
Camille GagnonCanadian Medication Appropriateness and Deprescribing Network, Centre de Recherche, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada.ORCID 0000-0003-4576-6336
Danijela GnjidicSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0002-9404-3401
Lisa Kouladjian O'DonnellSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0003-0927-7295
Elizabeth ManiasFaculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-3747-0087
Lisa M McCarthyLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-9087-1077
Frank MoriartySchool of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID 0000-0001-9838-3625
Jérôme Nguyen-SoenenDepartment of General Practice, Faculty of Medicine, Nantes Université, Nantes, France.ORCID 0000-0002-6023-8892
Sion ScottSchool of Health Sciences, University of East Anglia, Norwich, United Kingdom.ORCID 0000-0001-7669-0632
Michael A SteinmanDivision of Geriatrics, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-9564-9480
Petra A ThürmannDepartment of Clinical Pharmacology, Faculty of Health, Witten/Herdecke University, Witten, Germany.ORCID 0000-0001-9724-1422
Marnie Goodwin WilsonDivision of General Internal Medicine and Critical Care, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-5180-0831
Bianca J GutmanPatient Partner, Montreal, QC, Canada.
Arielle MendelDivision of Clinical and Translational Research, Faculty of Medicine and Health Sciences, McGill University, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada, 1 (514) 934-1934 ext 36134.ORCID 0000-0001-9732-616X
Emilie TrinhDivision of Clinical and Translational Research, Faculty of Medicine and Health Sciences, McGill University, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada, 1 (514) 934-1934 ext 36134.ORCID 0000-0001-8479-6656
Todd C LeeDivision of Clinical and Translational Research, Faculty of Medicine and Health Sciences, McGill University, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada, 1 (514) 934-1934 ext 36134.ORCID 0000-0002-2267-4239
Emily G McDonaldDivision of Clinical and Translational Research, Faculty of Medicine and Health Sciences, McGill University, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada, 1 (514) 934-1934 ext 36134.ORCID 0000-0003-0783-0624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Polypharmacy is increasingly common across all age groups and is often associated with the use of potentially inappropriate medications (PIMs), where harms may outweigh benefits, contributing to increased adverse drug events, reduced quality of life, and rising health care costs. However, existing deprescribing guidelines and PIM criteria, such as the Beers Criteria and STOPP/START (Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert to Right Treatment), primarily target older adults, overlooking the risks faced by younger populations. Objective: This study aims to develop an international consensus-based list of PIMs for adults aged 18 to 65 years through a modified Delphi process, addressing a critical gap in medication safety and deprescribing guidance. Methods: A 14-member international steering committee developed a preliminary list of candidate PIMs through a literature review and expert input. An international, interdisciplinary Delphi panel of 30 to 40 participants will evaluate this list across 3 survey rounds. Panelists will rate the relevance of potential PIMs using predefined criteria, including the balance of benefits and harms, patient preferences, and the availability of alternatives. Consensus will be defined as a median rating of ≥4 (for inclusion) or ≤2 (for exclusion) on a 5-point Likert scale (1=not relevant to 5=extremely relevant), with an IQR width of ≤1 and at least 70% directional agreement. Items not meeting thresholds will be carried forward to subsequent rounds for reconsideration. Quantitative analyses will summarize ratings and agreement levels, while qualitative free-text responses will undergo content analysis to provide context and capture nuanced perspectives. The process will yield a prioritized list of PIMs for adults aged 18 to 65 years. Results: Panel recruitment was completed between September and October 2025, with 36 participants. Three rounds of data collection were completed between October 2025 and January 2026. Interim analyses were conducted to inform structured feedback between rounds. Final data analysis is ongoing, and consensus results are expected to be reported in late 2026. Conclusions: This Delphi process will yield a consensus-based list of PIMs for adults aged 18 to 65 years, informing the development of an international guideline to support safer prescribing practices and to expand deprescribing efforts beyond geriatric care.

Indexed as

Inappropriate PrescribingPotentially Inappropriate Medication ListAdolescentAdultAgedConsensusDelphi TechniqueFemaleHumansMiddle AgedPolypharmacyResearch Designadult populationconsensus developmentDelphi techniquedeprescribingmedication appropriatenesspolypharmacypotentially inappropriate medicationsstudy protocol

Identifiers

PMID42398036
PMCPMC13331326

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.